Geode Capital Management’s Definium Therapeutics DFTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$47.2M Buy
2,495,399
+162,461
+7% +$2.76M ﹤0.01% 1522
2025
Q4
$31.2M Buy
2,332,938
+508,237
+28% +$6.29M ﹤0.01% 1763
2025
Q3
$21.5M Buy
1,824,701
+91,247
+5% +$851K ﹤0.01% 1966
2025
Q2
$11.3M Buy
1,733,454
+66,663
+4% +$438K ﹤0.01% 2283
2025
Q1
$9.75M Sell
1,666,791
-56,297
-3% -$403K ﹤0.01% 2307
2024
Q4
$12M Buy
1,723,088
+45,386
+3% +$312K ﹤0.01% 2253
2024
Q3
$9.55M Buy
1,677,702
+162,933
+11% +$1.13M ﹤0.01% 2411
2024
Q2
$10.9M Buy
1,514,769
+1,125,365
+289% +$9.84M ﹤0.01% 2268
2024
Q1
$3.66M Buy
389,404
+11,489
+3% +$65.5K ﹤0.01% 2864
2023
Q4
$1.38M Buy
377,915
+6,602
+2% +$19.9K ﹤0.01% 3218
2023
Q3
$1.16M Buy
371,313
+303
+0.1% +$1.25K ﹤0.01% 3261
2023
Q2
$1.32M Buy
371,010
+30,955
+9% +$107K ﹤0.01% 3248
2023
Q1
$1.08M Buy
340,055
+58,384
+21% +$194K ﹤0.01% 3310
2022
Q4
$619K Buy
+281,671
New +$782K ﹤0.01% 3567
2022
Q3
Sell
-13,410
Closed -$129K 5036
2022
Q2
$129K Sell
13,410
-174,769
-93% -$2.21M ﹤0.01% 4481
2022
Q1
$3.13M Sell
188,179
-5,737
-3% -$99.5K ﹤0.01% 3037
2021
Q4
$4.01M Sell
193,916
-286
-0.1% -$9.13K ﹤0.01% 3012
2021
Q3
$6.79M Buy
194,202
+13,396
+7% +$579K ﹤0.01% 2728
2021
Q2
$9.36M Buy
+180,806
New +$9.49M ﹤0.01% 2504

Other funds holding DFTX

Geode Capital Management's DFTX Position: Q1 2026 in Review

Geode Capital Management increased its Definium Therapeutics (DFTX) stake by 7% in Q1 2026, buying an estimated $2.76M and bringing the position to 2,495,399 shares worth $47.2M. The position accounts for ﹤0.01% of the portfolio, ranked #1522.

Geode Capital Management first reported a position in DFTX in Q2 2021 and has held it in 19 quarters since. 247 funds tracked by Wall St. Rank hold DFTX as of Q1 2026.

  • Geode Capital Management held 2,495,399 shares of Definium Therapeutics worth $47.2M as of Q1 2026.
  • Geode Capital Management bought 162,461 Definium Therapeutics shares in Q1 2026, an estimated $2.76M.
  • Definium Therapeutics made up ﹤0.01% of Geode Capital Management's portfolio in Q1 2026, its #1522 holding.
  • Geode Capital Management first reported a position in Definium Therapeutics in Q2 2021 and has held it in 19 quarters since.
  • 247 funds tracked by Wall St. Rank held Definium Therapeutics as of Q1 2026.

Based on Geode Capital Management's 13F filing for Q1 2026, filed 15 May 2026.